Morgan Stanley initiated coverage on Vigil Neuroscience with a new price target

2/1/22 7:54:54 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Morgan Stanley initiated coverage of Vigil Neuroscience with a rating of Equal-Weight and set a new price target of $17.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VIGL

Date	Price Target	Rating	Analyst
5/28/2025	$8.00	Buy → Hold	Stifel
12/4/2024		Outperform	William Blair
12/19/2023	$13.00 → $4.00	Equal-Weight → Underweight	Morgan Stanley
10/18/2023	$23.00	Mkt Outperform	JMP Securities
3/31/2023	$15.00	Buy	Mizuho
9/16/2022	$19.00	Outperform	Wedbush
8/29/2022	$24.00	Buy	H.C. Wainwright
2/1/2022	$17.00	Equal-Weight	Morgan Stanley